Canopy Growth's Losses Narrow Sharply, But the Stock Chart Tells a Different Story
Published on 08/11/2026 at 17:13 | Redaktion boerse-global.de
The gap between operational progress and market perception rarely gets wider than it is right now for Canopy Growth. The cannabis producer delivered a quarterly report on Friday that beat analyst expectations on the bottom line, yet the share price remains mired in a prolonged slump that stretches back more than a year.
Investors did take some encouragement this week, however. The stock climbed 4.87 percent on Tuesday to EUR 0.8662, building on a 6.94 percent gain the previous session. The bounce followed the earnings release and a scheduled appearance by chief executive Luc Mongeau at the Canaccord Genuity Growth Conference in Boston on Tuesday.
A Quarter That Beat the Street
For the first quarter of fiscal 2027, Canopy Growth reported net revenue of CAD 81.2 million, up 13 percent from the same period a year earlier. The loss per share came in at minus USD 0.02, comfortably ahead of the minus USD 0.04 that analysts had penciled in.
The adjusted gross margin improved to 31 percent, up from 25 percent in the year-ago quarter. More striking was the trajectory of the adjusted EBITDA loss, which contracted by 59 percent — or CAD 4.7 million — to CAD 3.2 million. Management attributed the improvement to revenue growth across both segments and ongoing cost savings, though it noted that a reduced reimbursement rate for medical cannabis in Canada had partially offset those gains.
The company ended the quarter with CAD 337 million in cash.
Should investors sell immediately? Or is it worth buying Canopy Growth?
Growth Across the Board, Not Just in One Corner
What distinguishes this quarter from earlier bright spots is the breadth of the expansion. The Canadian medical cannabis market grew 22 percent, recreational cannabis in Canada rose 10 percent, and international cannabis markets also advanced 10 percent. Even the Storz & Bickel vaporizer division chipped in with 6 percent growth.
The cannabis business overall climbed 14 percent, providing the core momentum behind the group's numbers.
Management reaffirmed its expectation of year-over-year revenue growth for the full fiscal year and reiterated its goal of reaching positive adjusted EBITDA during the year. Near-term guidance points to gross margins in the mid-30 percent range, with a longer-term ambition of moving closer to 50 percent.
Strategic Moves and New Markets
The company is pressing ahead with its international expansion. First shipments of dried cannabis flower to the United Kingdom are expected to begin shortly, with management anticipating revenue contributions from that market in the second half of fiscal 2027.
The acquisition of MTL Cannabis, completed in March, is also expected to bear fruit. Canopy Growth says the deal positions it as the leading medical cannabis platform in Canada by revenue and strengthens its foothold in international medical markets, including Europe. The company anticipates annual synergies of CAD 8 million from the transaction.
The Market Remains Skeptical
Despite the improving fundamentals, the stock's longer-term trajectory tells a more sobering story. The shares closed at EUR 0.8400 in the most recent session before Tuesday's bounce, and even after the two-day rally, the stock remains down 16.87 percent year to date. Over the past twelve months, the decline stands at 37.14 percent.
Canopy Growth at a turning point? This analysis reveals what investors need to know now.
The gap to the 52-week high of EUR 2.00, reached in December, is a daunting 57.96 percent. The shares also trade 8.72 percent below their 200-day moving average of EUR 0.9489.
The market's hesitance is understandable in one respect: a narrower loss is not yet a profit. The distance between an improved gross margin and genuinely black ink remains considerable, and the broader cannabis sector has yet to fully reclaim the investor enthusiasm that defined its earlier years.
What Comes Next
Mongeau's presentation at the Boston conference on Tuesday gave institutional investors a chance to hear directly from management about whether the growth dynamics across all segments can be sustained in the coming quarters. The question hanging over the stock is whether this quarter represents the beginning of a durable trend or a one-off improvement.
The next quarterly report, scheduled for November 6, 2026, will provide the first real test of whether the operational momentum can be maintained — and whether the market's patience will eventually be rewarded.
Ad
Canopy Growth Stock: New Analysis - 11 August
Fresh Canopy Growth information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
